H-Pharm's Propin capsule designated as first bioequivalence test-waivered item

The Korea Food and Drug Administration (KFDA) announced that H-Pharm's antidepressant Propin capsule (fluoxetine HCl) was granted as the first bioequivalence test-waivered item, since its policy of expanding the waiver scope of bioequivalence test on June 20 this year.

A KFDA official said that the formulation of Propin capsule, including the supplier of all ingredients, is identical with th...